What we invest in

AI ENABLED
PRECLINICAL &
CLINICAL
ACCELERATION

We invest in companies led by teams with experience in clinical setting and or drug development, with a strong data moat and a business model enabling to develop partnerships with pharma.

  • AI driven drug discovery
  • Personalised Medicine
  • Enabling tech for pre-clinical and clinical trial
  • Pre-clinical translation model discovery

NEXT-GEN
DIAGNOSTICS,
THERAPEUTICS &
MONITORING

We invest in companies that bridge the gap between patients and healthcare through AI-enabled digital solutions, improving care delivery, accessibility, and addressing areas of high unmet medical need.

  • AI-Powered Diagnostics and Imaging Tools
  • Digital Therapeutics (DTx) & Virtual Care
  • Remote Patient Monitoring (RPM)
  • Healthcare Workforce Augmentation

NEXT-GEN
BIOLOGICS &
BIOMANU-
FACTURING

We invest in companies with breakthrough scientific discoveries that can create flexible, scalable platforms – reducing the risk of investing in traditional single-asset Biotechs.

  • Platform technologies for next-gen biologics design
  • Biomanufacturing
  • Synthetic Biology & Programmable Biologics
  • Scalable delivery technologies for advanced therapeutics

500K-2mio EUR

Initial ticket size

(Pre-) Seed & Series A

Stages

Europe

Geography

Portfolio entrepreneurs about Health & Bio

OUR HEALTH & BIO PORTFOLIO

Steffen Wagner

Steffen Wagner

Co-Founder & Co-CEO

Xavier Mesnier

Principal
Rebecca Laurent

Rebecca Laurent

Investment Associate
Bernardo Delarue Bizzini

Bernardo Delarue Bizzini

Scientific Advisor

WITH US, YOU CAN CO-INVEST WITH THEM

Verve's investor network

We’re not alone in our mission. We co-invest with some of the most sophisticated venture capital firms focusing on industrial change. And our network of qualified private investors can co-invest with us alongside these firms. If you want to contribute to solving the challenges of human health with your health & bio investments, you should join us.

Health & Bio Co-Investors

Frequently Asked Questions

With over 10 years of experience and 30+ investments under the healthcare umbrella, and driven by the large network of LPs and portfolio founders, we are one of the few European investors with the technical, commercial, and operational expertise in growing the companies, and supporting on market entry, expansion, technical scalability, biopharma partnerships, and fundraising.

While we do not invest in single asset or single indication therapeutics, we have invested and will continue to invest in platform technologies that allow for development of multiple assets applicable across multiple indications or allow for licensing of the technology for co-developing assets with biopharma.

Yes! We have a mix of hardware and software only companies in our portfolio. However, we believe in owning the entire value chain and that real differentiation comes from building at the intersection of multiple disciplines.

With over 10 years of experience in high tech investments and technical founding teams, we understand the specific challenges and opportunities of scaling such startups. We have built an extensive network of advisors, co-investors, partners and potential clients that is at your disposal.As DeepTech investors we understand the timelines in TechBio and are able to provide capital for the long run. We focus on long-term company building and value generation rather than short-term optimization.

Yes, you could find us in local health & bio events in the EU and the UK, and the large healthcare conferences (e.g., JPM, LSX). However, you do not need to wait for an in person meeting. You are welcome to contact our health & bio team with a brief summary about yourself and your company.

The right timing for a funding round can vary depending on your specific business. Generally, being able to show an MVP or even a full product, first market traction through LOIs or POCs, as well as a well-functioning core team and ideally product market fit are decisive factors.We’d like to get to know you and your team early on. Therefore, we are also happy to start an initial conversation without first market traction or if you are not fundraising at the moment. We suggest reaching out to the one of the health & bio team members above.